Panel of experts discussing targeted therapies to deliver improved patient outcomes in oncology.
White Paper on Kidney Health: Developing Therapies for C3 Glomerulopathy
Abstract Randomized clinical trials are underway to evaluate the efficacy of novel agents targeting the alternative complement pathway in patients with C3 glomerulopathy (C3G), a rare glomerular disease. The Kidney Health Initiative convened a panel of experts in C3G to (1) assess the data supporting the use of the prespecified trial end points as measures of clinical benefit and (2) opine on efficacy findings they would consider compelling as treatment(s) of C3G in native kidneys.
View more resources in the AMCP Chronic Kidney Disease Resource Center.
Sponsored by Apellis
©2025 Apellis Pharmaceuticals, Inc. All rights reserved. 1/25 US-C3G-2500007 v1.0
Related
Exploring opportunities to improve the quality of life for those with Amyotrophic Lateral Sclerosis (ALS)
Chronic Kidney Disease is when the kidneys gradually get damaged over time and the kidneys are unable to complete functions such as removing wastes from your body, maintain blood pressure, and keeping your bones healthy.
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
